肥胖与卵巢癌的相关性

doi:10.3760/cma.j.issn.1673-422X.2015.02.019

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (2): 150-152.doi: 10.3760/cma.j.issn.1673-422X.2015.02.019

肥胖与卵巢癌的相关性

李霞辉,张学梅,蒋葵

116027大连医科大学附属第二医院肿瘤内科（李霞辉、蒋葵）；大连大学医学院（张学梅）

出版日期:2015-02-08 发布日期:2015-02-02
通讯作者: 蒋葵 E-mail:jk0411@163.com
基金资助:
国家科技支撑计划（2012BAK25B00）

Correlation between obesity and ovarian cancer

Li Xiahui, Zhang Xuemei, Jiang Kui

Department of Medical Oncology, Second Hospital of Dalian Medical University, Dalian 116027, China

Online:2015-02-08 Published:2015-02-02
Contact: Jiang Kui E-mail:jk0411@163.com

摘要/Abstract

摘要： 肥胖不仅增加卵巢癌的发生危险，而且与卵巢癌的不良预后相关。其病因学机制可能与肥胖引起雌激素、胰岛素及胰岛素样生长因子水平升高，以及多种脂肪细胞因子等因素共同作用相关，影响卵巢癌的治疗效果和预后。因此，保持合适的体重可以预防和控制卵巢癌的发生和发展。

关键词: 肥胖症, 卵巢肿瘤, 人体质量指数

Abstract: Obesity increases the risk of ovarian cancer, and it is associated with the poor prognosis of ovarian cancer. Its pathogenic mechanism may be associated with the increased level of serum estrogen, insulin and insulinlike growth factors1 induced by obesity and a variety of adipocytokines, which has an impact on the therapeutic result and prognosis of ovarian cancer. Maintaining a proper weight may prevent the development of ovarian cancer.

Key words: Obesity, Ovarian neoplasms, Body mass index

李霞辉,张学梅,蒋葵. 肥胖与卵巢癌的相关性[J]. 国际肿瘤学杂志, 2015, 42(2): 150-152.

Li Xiahui, Zhang Xuemei, Jiang Kui. Correlation between obesity and ovarian cancer[J]. Journal of International Oncology, 2015, 42(2): 150-152.

参考文献

［1］ Guo L, Li N, Wang G, et al. Body mass index and cancer incidence: a prospective cohort study in northern China［J］. Zhonghua Liu Xing Bing Xue Za Zhi, 2014, 35(3): 231-236. ［2］ Poorolajal J, Jenabi E, Masoumi SZ. Body mass index effects on risk of ovarian cancer: a metaanalysis［J］. Asian Pac J Cancer Prev, 2014, 15(18): 7665-7671. ［3］ Olsen CM, Nagle CM, Whiteman DC, et al. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium［J］. Endocr Relat Cancer, 2013, 20(2): 251-262. ［4］ Canchola AJ, Chang ET, Bernstein L, et al. Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort［J］. Cancer Causes Control, 2010, 21(12): 2241-2248. ［5］ De Stefano I, Zannoni GF, Prisco MG, et al. Cytoplasmic expression of estrogen receptor beta (ERbeta) predicts poor clinical outcome in advanced serous ovarian cancer［J］. Gynecol Oncol, 2011, 122(3): 573-579. ［6］ Lu Z, Zhang Y, Yan X, et al. Estrogen stimulates the invasion of ovarian cancer cells via activation of the PI3K/AKT pathway and regulation of its downstream targets Ecadherin and alphaactinin4［J］. Mol Med Rep, 2014, 10(5): 2433-2440. ［7］ Tas F, Karabulut S, Serilmez M, et al. Clinical significance of serum insulinlike growth factor1 (IGF1) and insulinlike growth factor binding protein3 (IGFBP3) in patients with epithelial ovarian cancer［J］. Tumour Biol, 2014, 35(4): 3125-3132. ［8］ Zhang Y, Daquinag AC, AmayaManzanares F, et al. Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment［J］. Cancer Res, 2012, 72(20): 5198-5208. ［9］ Chen C, Chang YC, Lan MS, et al. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways［J］. Int J Oncol, 2013, 42(3): 1113-1119. ［10］陈仲. 脂联素蛋白的纯化方法及卵巢癌ES2体外抑瘤活性研究［D］. 北京: 中国协和医科大学, 2007. ［11］ Dalamaga M. Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives［J］. Biomark Med, 2014, 8(1): 107-118. ［12］ Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth［J］. Nat Med, 2011, 17(11): 1498-1503. ［13］ Fotopoulou C, Richter R, Braicu EI, et al. Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking［J］. Ann Surg Oncol, 2011, 18(9): 2629-2637. ［14］ Worley MJ Jr, Guseh SH, RauhHain JA, et al. What is the optimal treatment for obese patients with advanced ovarian carcinoma?［J］. Am J Obstet Gynecol, 2014, 211(3): 231.e1-9. ［15］ Barrett SV, Paul J, Hay A, et al. Does body mass index affect progressionfree or overall survival in patients with ovarian cancer? Results from SCOTROC Ⅰ trial［J］. Ann Oncol, 2008, 19(5): 898-902. ［16］ Wright JD, Tian C, Mutch DG, et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study［J］. Gynecol Oncol, 2008, 109(3): 353-358. ［17］ AuYeung G, Webb PM, DeFazio A, et al. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)［J］. Gynecol Oncol, 2014, 133(1): 16-22. ［18］ Slaughter KN, Thai T, Penaroza S, et al. Measurements of adiposity as clinical biomarkers for firstline bevacizumabbased chemotherapy in epithelial ovarian cancer［J］. Gynecol Oncol, 2014, 133(1): 11-15.

[1]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[2]	安荣, 刘美华, 王佩晨, 王晓慧. Nrf2在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(8): 493-497.
[3]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[4]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[5]	李晨曦, 赵宏伟. PARP抑制剂治疗铂耐药卵巢癌的研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 180-183.
[6]	李哲丰, 李洁, 赵晓婷, 岳文涛. GLDC通过PI3K/Akt/mTOR通路调控卵巢癌细胞的增殖与凋亡[J]. 国际肿瘤学杂志, 2021, 48(12): 716-722.
[7]	关若丹, 摘译. 奥拉帕利对携带BRCA突变的新诊断晚期卵巢癌、原发性腹膜癌、输卵管癌患者维持治疗的有效性研究:SOLO1试验的亚组分析(摘译)[J]. 国际肿瘤学杂志, 2021, 48(12): 764-768.
[8]	郑静, 姚胜, 沈文洁, 孙志佳, 赵辉, 付艳, 高珂, 杜楠. 腹腔灌注贝伐珠单抗联合白蛋白紫杉醇和卡铂治疗卵巢癌所致癌性腹腔粘连的临床探讨[J]. 国际肿瘤学杂志, 2021, 48(11): 660-665.
[9]	杨立芬, 宋伟, 许大伟, 武军, 高然. miR-103a-3p/CHI3L1在卵巢癌细胞增殖和血管拟生中的作用机制[J]. 国际肿瘤学杂志, 2020, 47(6): 333-339.
[10]	薛晨, 赵月, 石光, 唐艳. PD-1/PD-L1抑制剂在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2020, 47(5): 312-315.
[11]	杨怡婷, 程忠平. 炎症细胞因子在卵巢上皮癌化疗耐药中的作用[J]. 国际肿瘤学杂志, 2020, 47(4): 249-251.
[12]	樊阳阳, 王影, 袁峰, 杜善平, 贺荣荣, 加燕. MALAT1靶向miR-142-3p在卵巢癌化疗耐药中的机制研究[J]. 国际肿瘤学杂志, 2020, 47(2): 82-89.
[13]	权瑞泉, 张丽, 匡黎, 李洪波, 肖梅仙. 奥拉帕尼联合贝伐珠单抗治疗复发性铂类敏感卵巢癌患者的疗效及对血清HE4、CA125、CTC水平的影响[J]. 国际肿瘤学杂志, 2020, 47(10): 606-610.
[14]	唐南敏, 于占彩. 转化生长因子-β通路与卵巢癌靶向治疗[J]. 国际肿瘤学杂志, 2019, 46(9): 562-565.
[15]	褚超男,黄琪. 脂质体多柔比星单药与吉西他滨联合奥沙利铂对复发性铂耐药卵巢癌患者的疗效及安全性比较[J]. 国际肿瘤学杂志, 2019, 46(1): 32-35.

肥胖与卵巢癌的相关性

Correlation between obesity and ovarian cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价